Regadenoson
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Regadenoson |
| DrugBank ID | DB06213 |
| Brand Names (EU) | Rapiscan |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.85% |
Approved Indication (EMA)
This medicinal product is for diagnostic use only. Rapiscan is a selective coronary vasodilator for use as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients unable to undergo adequate exercise stress.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | anaphylaxis | 99.85% | DL |
| 2 | food-dependent exercise-induced anaphylaxis | 99.74% | DL |
| 3 | esotropia | 99.12% | DL |
| 4 | pseudoallergy | 99.12% | DL |
| 5 | headache disorder | 98.01% | DL |
| 6 | migraine disorder | 97.14% | DL |
| 7 | trigeminal autonomic cephalalgia | 97.00% | DL |
| 8 | migraine with brainstem aura | 96.93% | DL |
| 9 | bronchial disease | 96.76% | DL |
| 10 | glossodynia | 95.87% | DL |
| 11 | coccygodynia | 95.82% | DL |
| 12 | Raynaud disease | 95.68% | DL |
| 13 | endobronchial leiomyoma | 95.64% | DL |
| 14 | bronchus adenoma | 95.55% | DL |
| 15 | endobronchial lipoma | 95.54% | DL |
| 16 | atypical coarctation of aorta | 95.26% | DL |
| 17 | scalp dermatosis | 95.19% | DL |
| 18 | primary hereditary glaucoma | 95.12% | DL |
| 19 | neuralgia | 95.02% | DL |
| 20 | thrombotic disease | 94.94% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.